z-logo
Premium
The Human Promyelocytic Leukemia Cell (HL‐60 Cell) β‐Adrenergic Receptor
Author(s) -
Sager G.,
Bang B.E.,
Pedersen M.,
Aarbakke J.
Publication year - 1988
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1002/jlb.44.1.41
Subject(s) - receptor , endocrinology , medicine , cyclase , atenolol , biology , adenylate kinase , adrenergic receptor , potency , antagonist , adrenergic , agonist , radioligand , alprenolol , epinephrine , adrenergic antagonist , biochemistry , in vitro , blood pressure
We have characterized the β‐adrenergic receptor binding site and the β‐adrenergic cAMP response of the HL‐60 cell. The hydrophilic ligand [ 3 H]‐(–)‐CGP‐12177 was specifically and reversibly bound to one single class of binding sites (K d 220 pM and B max 1,970 sites/cell). The adrenergic agonists inhibited the specific radioligand binding. The order of potency was isoproterenol > epinephrine > norepinephrine. The β‐2 selective antagonist ICI 118551 had a binding affinity 3 orders of potency higher than the β‐1 selective antagonist, atenolol. The adrenergic agonists elevated the cAMP accumulation in a concentration‐dependent mode. The order of potency was isoproterenol > epinephrine > norepinephrine. Both the binding and the functional studies revealed stereospecificity and reversibility. The present data show that HL‐60 cells possess β‐2 adrenergic receptors functionally coupled to adenylate cyclase.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here